US-based radiopharmaceutical company Lantheus has announced a definitive agreement to acquire clinical-stage radiopharma contract development and manufacturing organisation (CDMO) Evergreen ...

Prostate imaging drug Pylarify has become the first radiodiagnostic blockbuster, achieving over $1 billion in sales for 2024. The addressable market continues to expand.

LNTH READ THE FULL LNTH RESEARCH REPORT Lantheus Holdings, Inc. (NASDAQ:LNTH) reported 2024 financial and operational results on February 26 th , producing sales of over $1 billion for Pylarify during ...

Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024Free cash flow was $141.4 million and $493.1 ...

Lantheus, a Massachusetts-based developer of radiopharmaceuticals, has agreed to acquire the radiopharma contract development and manufacturing organization (CDMO) Evergreen Theragnostics.

Well before market open that morning, Lantheus announced that it has signed a definitive agreement to acquire clinical-stage peer Evergreen Theragnostics. For its new asset, Lantheus will make an ...

Welcome to the Lantheus Fourth Quarter and Full Year 2024 Conference Call. [Operator Instructions]. This call is being recorded and a replay will be available in the Investors section of the company's ...

Lantheus is enhancing its radiopharmaceutical ... the agreements to acquire Life Molecular and Evergreen Theragnostics. Both acquisitions are expected to close in the second half of 2025, subject ...